Royal Philips has introduced the new HeartStart Intrepid monitor/defibrillator to assess and treat patients in medical emergencies across pre-hospital and hospital settings.
In hospitals, the device can be used by clinicians to evaluate a patient and provide the necessary intervention, including defibrillation in case of a sudden cardiac arrest.
Philips designed the HeartStart Intrepid monitor/defibrillator to be portable, lightweight and rugged for emergency medical service (EMS) use and transport within a hospital.
Vital patient monitoring parameters and diagnostic measurements from the device can accelerate triage and facilitate treatment decisions, added Philips.
The device comes with QCPR functionality that offers CPR feedback and guidance for compressions and ventilations.
It also has Traumatic Brain Injury (TBI) Advisory, which leverages vital sign evaluation to deliver the visual guidance required to avoid serious complications in people with suspected TBI.
The device features the company’s IntelliSpace Connect data management solution, which enables loading of emergency event data into electronic patient care reporting (ePCR) and electronic medical records (EMR/EHR).
This process is intended to offer correct event documentation for billing and secure storage of data for post-event review aimed at improving quality.
IntelliSpace Connect is powered by the Philips HealthSuite Cloud platform and can be accessed via a browser. The data management solution is intended to offer a cost-effective option for hospitals.
Royal Philips Therapeutic Care business leader Arman Voskerchyan said: “A full range of monitoring capabilities and decision support tools let emergency staff quickly evaluate and treat patients in life-threatening situations.
“Enhanced connectivity between care settings helps to streamline communication and improve clinical workflow for caregivers, ultimately allowing them to provide patients with better care.”
Philips HeartStart Intrepid monitor/defibrillator has secured CE-Mark approval and is now commercially available in Europe and certain Asian and African markets.